Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani M, Martinelli G.
Soverini S, et al. Among authors: merante s.
Blood. 2009 Sep 3;114(10):2168-71. doi: 10.1182/blood-2009-01-197186. Epub 2009 Jul 9.
Blood. 2009.
PMID: 19589924
Free article.